Data Sheet (Cat.No.T61884)

TargetMol

C6 Ceramide

Chemical Properties



CAS No. : 124753-97-5

Formula: C24H47NO3

Molecular Weight: 397.63

Storage: Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	C6 Ceramide (N-hexanoylsphingosine) is an activator of the ceramide pathway that arrests cells in the G0/G1 phase by activating ERK. It can act in a variety of cancer cell lines.
Targets(IC50)	Apoptosis

Solubility Information

Solubility	DMSO: 90 mg/mL (226.34 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (8.3 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5149 mL	12.5745 mL	25.149 mL
5 mM	0.503 mL	2.5149 mL	5.0298 mL
10 mM	0.2515 mL	1.2575 mL	2.5149 mL
50 mM	0.0503 mL	0.2515 mL	0.503 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Zhu Q, et, al. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis. 2011 Jan 27;2(1): e117.

Liu L, et, al. C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway. J Transl Med. 2020 Aug 3;18(1):298.